

To,

<b>National Stock Exchange of India Limited</b> Exchange Plaza, C-1, Block G, Bandra Kurla Complex, Bandra (East), Mumbai - 400 051	<b>BSE Limited</b> P J Towers, Dalal Street, Mumbai- 400 001
<b>Script Symbol: EMCURE</b>	<b>Scrip Code/Symbol: 544210/ EMCURE</b>

Dear Sir/Madam,

**Subject: Intimation under Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ('SEBI Listing Regulations')**

Pursuant to Regulation 30 of the SEBI Listing Regulations and based on the recommendation of the Nomination and Remuneration Committee, we wish to inform you that the Board of Directors of the Company at its meeting held today i.e. Wednesday, February 04, 2026, has approved the re-appointment of the following Independent Directors for second consecutive term, subject to approval of shareholders:

- i. Dr. Shailesh Kripalu Ayyangar (DIN: 00268076) as Non-Executive and Independent Director for a second consecutive term of five (5) years with effect from June 02, 2026;
- ii. Mr. Vijay Keshav Gokhale (DIN: 09134089) as Non-Executive and Independent Director for a second consecutive term of five (5) years with effect from April 16, 2026;
- iii. Dr. Vidya Rajiv Yeravdekar (DIN: 02183179) as Non-Executive and Independent Director for a second consecutive term of three (3) years with effect from April 16, 2026

Dr. Shailesh Kripalu Ayyangar, Mr. Vijay Keshav Gokhale and Dr. Vidya Rajiv Yeravdekar are not debarred from holding the office of a Director by virtue of any Securities and Exchange Board of India ('SEBI') SEBI order and in accordance with BSE Circular No. LIST/COMP/14/2018-19 dated June 20, 2018 and NSE Circular No. NSE/CML/2018/02 dated June 20, 2018, or any such other authority, and that they are not related to any Director(s) or Key Managerial Personnel(s) of the Company.

The particulars of the disclosure required under Regulation 30 and Part A of Schedule III of the SEBI Listing Regulations are enclosed herewith.

**Emcure Pharmaceuticals Limited**

**Registered Office:** Plot No. P-1 & P-2, IT-BT Park, Phase-II, M.I.D.C., Hinjawadi, Pune - 411057, Maharashtra, India

**Phone Nos.:** +91 20 - 35070033/ 35070000 **Fax No.:** +91 20 3507 0060

**E-mail:** corporate@emcure.com **Website:** www.emcure.com **CIN:** L24231PN1981PLC024251

# Emcure

The meeting of the Board of Directors of the Company commenced at 12.40 p.m. (IST) and concluded at 1:15 p.m. (IST).

You are requested to kindly take the above on your records.

Thanking you,  
For **Emcure Pharmaceuticals Limited**

**Tajuddin Shaikh**  
**Chief Financial Officer**

*Encl: As above*

## **Emcure Pharmaceuticals Limited**

**Registered Office:** Plot No. P-1 & P-2, IT-BT Park, Phase-II, M.I.D.C., Hinjawadi, Pune - 411057, Maharashtra, India

**Phone Nos.:** +91 20 – 35070033/ 35070000 **Fax No.:** +91 20 3507 0060

**E-mail:** corporate@emcure.com **Website:** www.emcure.com **CIN:** L24231PN1981PLC024251

**Annexure**

**Disclosure under Para (A) of Part (A) of Schedule III to the Regulation 30 SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015:**

Sr. No.	Particulars	Information-		
		Dr. Shailesh Kripalu Ayyangar	Mr. Vijay Keshav Gokhale	Dr. Vidya Rajiv Yeravdekar
1	Reason for change viz. appointment re-appointment, <del>resignation, removal, death or otherwise</del>	Re-appointment as Non-Executive and Independent Director	Re-appointment as Non-Executive and Independent Director	Re-appointment as Non-Executive and Independent Director
2	Date of appointment/ re-appointment/ <del>cessation (as applicable)</del> & term of appointment/ re-appointment	Re-appointment with effect from June 02, 2026 for a second term of (five) 5 years, subject to approval of Members of the Company.	Re-appointment with effect from April 16, 2026 for a second term of (five) 5 years, subject to approval of Members of the Company.	Re-appointment with effect from April 16, 2026 for a second term of (three) 3 years, subject to approval of Members of the Company.
3	Brief profile (in case of appointment);	<p>Dr. Shailesh Kripalu Ayyangar has been associated with the Company since April 16, 2021, as Director of the Company.</p> <p>He is having over 40 years of experience in healthcare, has gained deep experience in pharmaceutical R&amp;D, Biologicals, Pharmaceutical operations, Animal Health, Consumer</p>	<p>Mr. Vijay Keshav Gokhale has been associated with the Company since April 16, 2021, as Director of the Company.</p> <p>Mr. Gokhale has done Masters in History and joined the Indian Foreign Service in 1981. His previous diplomatic assignments include postings in Hong Kong, Hanoi, Beijing and New York. He has also served as Deputy</p>	<p>Dr. Vidya Rajiv Yeravdekar has been associated with the Company since April 16, 2021, as Director of the Company.</p> <p>Dr. Vidya is the Principal Director of Symbiosis Society, and the Pro Chancellor of Symbiosis International University.</p> <p>Dr. Vidya has been appointed as a</p>

**Emcure Pharmaceuticals Limited**

**Registered Office:** Plot No. P-1 & P-2, IT-BT Park, Phase-II, M.I.D.C., Hinjawadi, Pune - 411057, Maharashtra, India

**Phone Nos.:** +91 20 – 35070033/ 35070000 **Fax No.:** +91 20 3507 0060

**E-mail:** corporate@emcure.com **Website:** www.emcure.com **CIN:** L24231PN1981PLC024251

		<p>Healthcare &amp; Strategic M&amp;A.</p> <p>He was the member of International Leadership Team of Sanofi and Country Chair for India &amp; South Asia running all business interests of the Sanofi Group including Pharmaceuticals, Specialty care, Vaccines, Animal Health and Consumer Healthcare. He built the business from its infancy to bringing it to be amongst the most respected and fast growing MNCs in India &amp; South Asia.</p> <p>Dr. Ayyangar holds a bachelor degree of veterinary science and animal husbandry from the Gujarat Agricultural University and a post graduate diploma in Management from Indian Institute of Management, Ahmedabad.</p>	<p>Secretary (Finance), Director (China &amp; East Asia) and Joint Secretary (East Asia) during his stints at the Headquarters of the Ministry of External Affairs. He was High Commissioner of India to Malaysia from January 2010 to October 2013, Ambassador of India to the Federal Republic of Germany from October 2013 to January 2016, and Ambassador of India to the People's Republic of China from January 2016 to October 2017. He served as Secretary (ER) from October 2017 to January 2018. Mr. Gokhale was Foreign Secretary from January 2018 to January 2020.</p>	<p>member of the expert group on Global Outreach of Higher Education, formulated by UGC to implement the National Education Policy 2020 that was rolled out by the Ministry of Education Govt. of India. She has been appointed as a member Advisory Group of Analytical and Advisory work (ASA), World Bank.</p> <p>Dr. Yeravdekar holds a degree in medicine, final MBBS and had done bachelors of Law from the University of Pune. Dr. Yeravdekar is also a qualified doctor of philosophy in internationalisation of higher education in India from Symbiosis International University.</p>
4	Disclosure of relationships between Directors (in case of appointment of a director).	Dr. Ayyangar is not related to any Director of the Company.	Mr. Gokhale is not related to any Director of the Company.	Dr. Yeravdekar is not related to any Director of the Company.

## Emcure Pharmaceuticals Limited

**Registered Office:** Plot No. P-1 & P-2, IT-BT Park, Phase-II, M.I.D.C., Hinjawadi, Pune - 411057, Maharashtra, India

**Phone Nos.:** +91 20 – 35070033/ 35070000 **Fax No.:** +91 20 3507 0060

**E-mail:** corporate@emcure.com **Website:** www.emcure.com **CIN:** L24231PN1981PLC024251